B+
Bull case
15%
Probability
Target price
$53.00
Analysis reference price unavailable
Analysis 2026-01-31 · RankAlpha Sentiment AI
GSK
GSKDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$45.50
Analysis reference price unavailable
Analysis 2026-01-31 · RankAlpha Sentiment AI
B-
Bear case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-01-31 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-01-31
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+40.6
Score
AI commentary
Market snippets show mixed-to-cautious analyst views with a median below current market price, signaling modest downside in base case [#SERP-1]. Some outlets report higher individual targets near $53, creating a narrow upside band versus a wide downside distribution in lower estimates [#SERP-3][#SERP-4]. Overall tone: cautious ahead of FY2025 results with attention on post-earnings revisions.
RankAlpha Sentiment AI - 2026-01-31
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-02-04eventFY2025 results and guidance releaseMedium impact
GSK to report FY2025 results and any guidance updates (market pages note FY2025 results expected 2026-02-04) — market reaction likely; see consensus reporting [#SERP-4].
2026-04-30catalystPost-earnings analyst target revisionsHigh impact
Analysts historically update 1–4 weeks after results; expect target/estimate revisions and note changes to median/high/low (assumption: review window ends by 2026-04-30) — informed by analyst target aggregators [#SERP-1],[#SERP-4].
2027-01-31catalystConsensus re-rating driven by strategy/pipeline executionHigh impact
Over 12 months, successful pipeline readouts, portfolio execution or sustained sales growth could push consensus toward the high end; see GSK analyst consensus bulletin [#SERP-8].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-31 • Updated nightlySource: Internal modelMethodology